BUSINESS PRESENTATION FOR TRUSTE LIGHTENER

DERMA MARKET Aug.'05 MAT

Market Size (US $ Mn) CAGR ( %) % Market Share in IPM No. of active players No. of active brands

350 9 5.17 100 1000

C-MARC & ORG IMS

CMARC: CPR

TOP INDICATIONS OF DERMATJULOCT'03 NOVFEB'04 INDICATIONS Rx TOTAL DERMATITIS ACNE VULGARIS FUNGAL INFECTION URTICARIA MELASMA PSORIASIS VITILIGO ALOPECIA PHOTODERMATITIS MARJUN'04

SEGMENT CHRONIC CHRONIC ACUTE ACUTE COSMETOLOGY CHRONIC CHRONIC COSMETOLOGY COSMETOLOGY

100.0 9.9 11.0 10.8 6.1 3.4 3.1 3.5 2.9 0.9

100.0 10.3 11.0 8.8 4.9 3.5 3.7 3.1 2.4 0.9

100.0 9.8 9.4 7.7 4.6 3.6 3.6 3.5 2.3 1.7

Disease segmentation 199917% 2%

Disease segmentation 200321% 3%

81%

76%

RETAIL AUDIT SALE IMSDisease segmentation 20077% 26%

67%

TYROSINE (AMINO ACID) TYROSINASE DOPA (Dihydroxyphenylalanine)

DOPAQUINONE

CYSTEINE OR GLUTATHIONE AUTO OXIDATION

CYSTEINYL DOPA OR GLUTATHIONE DOPA

DOPACHROME

PHENOMELANIN YELLOW OR RED PIGMENT

DI HYDROXYINDOLE OR DI HYDROXY-2 CARCOXYLIC ACID (DHCA) EUMELANIN (BROWN BLACK PIGMENT) DOPACHROME TAUTOMERASE AND DHCA OXIDASE

Principles of Therapy

Topical

de pigmenting agents:

Kligman formula Chemical peeling Microdermabrasion: Laser resurfacing:

ACTION TYROSINASE INHIBITOR

AGENTSHYDROQUINONE KOJIC ACID AZELAIC ACID LICORICE P-T ARBUTIN MELAWHITE ASCORBIC ACID, MAGNESIUM-L- ASCORBYL-2PHOSPHATE GLUTATHIONE AMMONIATED MERCURY ISOPROPYL CATECHOL N-ACETYL-4-S CYSTEMINYLPHENOL N-2,4-ACETOXYPHENYLTHIOETHYLACETAMIDE N- ACETYLCYSTEINE INDOMETHACIN CORTICOSTEROIDS

INHIBITION OF MELANIN PRODUCTION SELECTIVE MELANOCYTE TOXICITY

NONSELECTIVE SUPPRESSION OF MELANOGENESIS

HYDROQUINONE

HYDROQUINONE

TRETINOIN

KLIGMANS FORMULA

COMMON UNDESIRABLE EFFECTS OF KLIGMAN'S FORMULA

Facial Erythema Acneiform Eruptions Contact Dermatitis Increased Growth Of Vellus hair Leukoderma

KOJIC ACID (2-4% ) A fungal metabolic product produced by species of Aspergillus and Penicillium. Less effective than HQ, 2%. Inactivates Tyrosinase by the chelation of copper and suppresses the tautomerization from Dopachrome to 5,6-dihydroindole-2-carboxy acid A free radical scavenger. The main undesirable effect is mild facial erythema

OIL-SOLUBLE LICORICE EXTRACT The major component is Glabridin (10-40%). At the level of 50% inhibition of Tyrosinase activity, it has an efficacy 16 times greater than that of HQ. In the near future, HQ or Kojic acid will be replaced by licorice in a new and promising preparation for dermal melasma

ARBUTIN-THE SAFE HYDROQUINONE

Consists of a molecule of Hydroquinone bound to glucose . Competes with DOPA at it receptor site on Tyrosinase The percentage inhibition and efficacy are weaker than those observed for kojic acid.

Ascorbic acid

Glutathione

.

REMOVAL OF MELANIN

COMBINATION THERAPIESSynergic effect Shortens the duration of therapy Reduces the risk of adverse effect

DEMELANIZING AGENTS MELALITE CLEARZ MELACARE MELALITE-15 EUKROMA BRITE DEMELAN ESLITE HYCLEAN NPL DRL AJA NPL YSP WL/ GMK ELD RBY

MAT DEC 2004 UNITS 3,755,612 842,204 348,178 32,133 344,362 830,907 422,706 0 402,109 0

RUPEE 127,778,559 31,110,372 26,075,055 2,395,318 13,283,298 17,626,657 8,695,131 0 8,416,142 0

M.S. 100% 24% 20% 2% 10% 14% 7% 0% 7% 0%

MAT DEC 2005 UNITS 4,632,186 771,986 356,192 303,998 546,252 870,425 470,585 83,341 264,954 113,778

RUPEE 191,694,382 30,517,393 27,699,375 23,743,347 22,361,167 19,681,737 10,409,506 9,904,249 7,314,984 5,987,100

M.S 100% 16% 14% 12% 12% 10% 5% 5% 4% 3%

GROWT H 50% -2% 6% 891% 68% 12% 20% -13%

Sps. DERMAT200 180 160 140 120 100 80 60 40 20 0 BASE J-O'03 N-F'04

: Rx RESPONSE TRENDBASE :JAN. - DEC.2002 : FOUR MONTHLY AVG.:100

MELANIZING+DEME LANI+PEELING AG

DEMELANIZING AGENTS (DER)

MELANIZING AGENTS (DER)

J-O'04

N-F'05

J-O'05

M-J'04

M-J'05

N-F'06

MELANIZING+DEMELANI+PEELING AG

Sps: DERMATMOLECULE \ BRAND

Absolute :Rx Response Trend (Four Monthly)JULY'03- NOV'03- MAR'04- JUL'04OCT'03 FEB'04 JUNE'04 OCT'04 536 522 719 670 NOV'04- MAR'05- JULY'05- NOV'05FEB'05 JUNE'05 OCT'05 FEB'06 816 4 15 203 170 237 896 132 174 50 1 83 62 68 62 62 892 167 145 97 107 47 980 186 144 120 83 53 12 ] 11

DEMELANIZING AGENTS (DER)

MELACARE CREAM [AJNTA-ZILION] CLEARZ CREAM [DRL - RECURA] HYCLEAN CREAM [RBXY-CRL DER] DEMELAN CREAM [GLEN-GRACWEL] EUKROMA CREAM [YASH Pharma ] 76 KOJIC CREAM [CURATIO ]

BAN A TAN CREAM [CURATIO

MELANIZING AGENTS (DER)

808

690 105 84 69 41 70

769 124 95 75 55 73

693 96 98 71 55 69

678 99 96 70 66 54

707 99 86 83 55 50

679 86 76 62 73 62

644 79 70 61 49 46

1 PLACENTREX GEL [ALBERT DAVID] 42 MELANOCYL TAB [FRANCO (I) ] OCTAMOP TAB [PALSONS ] 95 94 59

VITILO LOTION [ELD-ELDERMIS]

68 PLACENTREX LOTION [ALBERT DAVID]

Drs currently need:

CURATIOS PRESENCE IN MELASMA MARKET

LICORICE ARBUTIN COSMOPERINE

KOJIC ACID 2%

RETAIL SALES14000 12000 10000 8000 6000 4000 2000 0 Oct- Nov- Dec- Jan05 05 05 06 Feb- Mar- Apr- May- Jun- Jul-06 Aug06 06 06 06 06 06 BANATAN KOJIC TOTAL

CURATIO GAINING Rx IN C-MARC DATA RANK 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 MELACARE MELALITE HYCLEAN CLEARZ CLEARZ PLUS EUKROMA DEMELAN MELALITE FORTE ESLITE BRITE VANISH BAN A TAN EUKROMA SG GLYAHA HQ KOJIC EUKROMA PLUS HYDE MAR-APR 06 1462 134 80 64 61 50 43 37 32 32 30 27 27 25 23 23 20 18 JAN-FEB 06 1479 116 81 74 103 30 34 59 31 29 32 25 10 28 21 10 11 24 28 26 37 49 61 34 27 50 MAR-APR 05 1353 72 72 11 103 PREV -17 18 -1 -10 -42 20 9 -22 1 3 -2 2 17 -3 2 13 9 -6 -10 -1 -14 -17 -29 -4 0 -7 CORR 109 62 8 53 -42

TRUSTE LIGHTENING ESSENCE Aqua, Cetearyl Ethylhexanoate, Cetearyl Alcohol, Butylene Glycol, Tocopheryl Acetate, Glycolic Acid, Kojic Dipalmitate. Arbutin, Lactic Acid, Sodium Lauryl Sulphate, Ascorbic Acid, Dimethicone, Sodium Sukphite, Arginine, Disodium EDTA, Phenoxyethanol, Solanum Lycopersicum (Tomato) Extract : Solano Complex

SWOTStrengths:Customer knowledge of the team Differentiated products Presence in Melasma Customer reach Credibility built in short time

Opportunities:High incidence of Melasma End consumer awareness gap. Growing affluence of customers Growing business potential per DR. Need for Niche and effective products.

Weaknesses:High investment required for CRM Initiatives.

Threats:Emergence of cosmetology players Entry of Global giants like VICHY Price barriers Players with Derma specific field force coming in Entrance of high end beauty parlors & Cosmetic clinics